Expression profile heatmaps of key genes in gene sets. by Jiyong Zhang (2498740)

Subjects:

Construction of the WGCNA Co-expression Network. by Jiyong Zhang (2498740)

Subjects:

Differential Gene Expression Associated with Non-Alcoholic Fatty Liver Disease. by Jiyong Zhang (2498740)

Subjects:

Interaction analysis of hub genes. by Jiyong Zhang (2498740)

Subjects:

Shares of antibiotic substances on total prescription in UTI treatment (N39.0, N30.0) by sex and age group in 2019 (female: n = 238.670 prescriptions; male: n = 40.641 prescription... by Thomas Hanslmeier (19949694)

Subjects:

Shares of antibiotic substances on total prescription by quarter from 2013 to 2019 for female and male patients with UTI (N39.0, N30.0)(female: n = 1.681.255 prescriptions; male: n... by Thomas Hanslmeier (19949694)

Subjects:

Shares of specialist groups prescribing 1^st, 2^nd, and 3^rd antibiotic prescriptions in UTI treatment of females (N39.0, N30.0) in 2018 and 2019. by Thomas Hanslmeier (19949694)

Subjects:

Number of antibiotic prescriptions in female and male patients with UTI (N30.0 and/or N39.0). by Thomas Hanslmeier (19949694)

Subjects:

Shares of antibiotic substances on total prescription in female patients with UTI (N39.0, N30.0) by physician specialties (GPs: n = 1.299.641 prescriptions; gynecologists n = 141.8... by Thomas Hanslmeier (19949694)

Subjects:

Comparison of 1^st, 2^nd, and 3^rd antibiotic prescription. by Thomas Hanslmeier (19949694)

Subjects:

UTI diagnoses by sex and physician specialty (2013–2019). by Thomas Hanslmeier (19949694)

Subjects:

Mean body weight of different groups at baseline and along four weeks of experimental procedures. by Deborah Ribeiro Frazão (9188152)

Western blotting identification of expression level of pyroptosis protein Gasdermin D (GSDMD) in IIL ESP-treated Caco-2 cells. by Qi Qi Lu (17721401)

Percent Decrease in FGM between Oldest (45-49 years) and Youngest (15-19 years) Cohorts of Women over the years in Egypt. by Shatha Elnakib (8901764)

Changes in the liver fibrosis-related markers in breast cancer patients with a FIB-4 index of >2.30 during letrozole treatment. by Kazuyoshi Ohkawa (836847)

Subjects:

Flowchart of patient selection in this study. by Kazuyoshi Ohkawa (836847)

Subjects:

Changes in the FIB-4 index in breast cancer patients with a FIB-4 index of ≥ 2.67 during letrozole and anastrozole treatment. by Kazuyoshi Ohkawa (836847)

Subjects:

Changes in the liver fibrosis-related markers in breast cancer patients with a FIB-4 index of >2.30 during anastrozole treatment. by Kazuyoshi Ohkawa (836847)

Subjects:

Clinical features and cancer treatment in patients with breast cancer receiving letrozole and anastrozole. by Kazuyoshi Ohkawa (836847)

Subjects:

S1 Data - by Kazuyoshi Ohkawa (836847)

Subjects: